# Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

> **NCT04842318** · PHASE4 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 789 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** BR for 6 cycles +R for 8 cycles
- **DRUG:** RCHOP for 6 cycles +R for 8 cycles
- **DRUG:** R2 for 6 cycles + R2 maintenance

## Key facts

- **NCT ID:** NCT04842318
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 789 (ESTIMATED)
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842318, "Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04842318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*